<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03147040</url>
  </required_header>
  <id_info>
    <org_study_id>M17GEL</org_study_id>
    <nct_id>NCT03147040</nct_id>
  </id_info>
  <brief_title>AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer</brief_title>
  <acronym>GELATO</acronym>
  <official_title>AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm multicenter non-randomized phase II trial testing the efficacy of the
      combination of carboplatin plus atezolizumab in metastatic ILC
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients free of progression at 6 months</measure>
    <time_frame>At 6 months</time_frame>
    <description>Progression as defined by RECST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients free of progression at 6 months in the IR profile subgroup</measure>
    <time_frame>At 6 months</time_frame>
    <description>as defined by retrospective gene expression profiling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients free of progression at 6 months in the non- IR profile subgroup</measure>
    <time_frame>At 6 months</time_frame>
    <description>as defined by retrospective gene expression profiling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients free of progression at 12 months</measure>
    <time_frame>At 12 months</time_frame>
    <description>as defined by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Assessed up to 60 months</time_frame>
    <description>Number of patients with a partial or complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Assessed up to one month after end of treatment</time_frame>
    <description>Adverse events will be graded according to NCI Common Toxicity Criteria version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Assessed up to 60 months</time_frame>
    <description>time from start treatment to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin/Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC=1.5, weekly schedule, maximum 12 administrations Atezolizumab, 1200 mg flat dose, 3-weekly schedule, starting after two administrations of carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Chemotherapy treatment with carboplatin and atezolizumab</description>
    <arm_group_label>Carboplatin/Atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Chemotherapy treatment with carboplatin and atezolizumab</description>
    <arm_group_label>Carboplatin/Atezolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and written informed consent

          -  Age 18 year or older

          -  Metastatic or incurable locally advanced lobular breast cancer with confirmation of
             the lobular histology and E-cadherin loss on a biopsy of a metastatic lesion.

          -  Metastatic lesion accessible for histological biopsies

          -  Evidence of progression of disease

          -  A maximum of two lines of palliative chemotherapy

          -  WHO performance status of 0 or 1

          -  Evaluable disease or measurable according to RECIST 1.1

        Exclusion Criteria:

          -  Leptomeningeal disease localization

          -  History of having received other anticancer therapies within 2 weeks of start of the
             study drug

          -  History of immunodeficiency, autoimmune disease, conditions requiring
             immunosuppression

          -  Prior treatment with immune checkpoint blockade

          -  Live vaccine within 2 weeks prior to start of study

          -  Active other cancer

          -  Active hepatitis B
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marleen Kok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marleen Kok, MD</last_name>
    <phone>+3120512</phone>
    <phone_ext>9111</phone_ext>
    <email>m.kok@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marleen Kok, MD</last_name>
      <phone>+3120512</phone>
      <phone_ext>9111</phone_ext>
      <email>m.kok@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid AM Mandjes, MSc</last_name>
      <phone>+3120512</phone>
      <phone_ext>9111</phone_ext>
      <email>i.mandjes@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Marleen Kok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C Schroder, MD</last_name>
    </contact>
    <investigator>
      <last_name>C Schroder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>V Tjan-Heijnen, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>V Tjan-Heijnen, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A Jager, MD</last_name>
    </contact>
    <investigator>
      <last_name>A Jager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lobular</keyword>
  <keyword>Metastatic or incurable locally advanced cancer</keyword>
  <keyword>Disease progression on endocrine therapy in advanced setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>to be decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

